This company listing is no longer active
ChemoCentryx (CCXI) Stock Overview
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CCXI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ChemoCentryx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$51.99 |
| 52 Week High | US$52.00 |
| 52 Week Low | US$14.95 |
| Beta | 1.23 |
| 1 Month Change | 0.41% |
| 3 Month Change | 134.51% |
| 1 Year Change | 50.39% |
| 3 Year Change | 558.10% |
| 5 Year Change | 642.71% |
| Change since IPO | 372.64% |
Recent News & Updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
ChemoCentryx shareholders have overwhelmingly approved Amgen's (NASDAQ:AMGN) $3.7B acquisition of the company. With the acquisition, Amgen (AMGN) gains access to Tavneos (avacopan), which is indicated for severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, a group of rare diseases characterized by destruction and inflammation of small vessels. NASDAQ said ChemoCentryx's (NASDAQ:CCXI) anticipated last day of trading will be Oct. 19.ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
ChemoCentryx press release (NASDAQ:CCXI): Q2 GAAP EPS of -$0.44 misses by $0.03. Revenue of $11.76M (+553.3% Y/Y) misses by $9.89M. On August 3, 2022, the company entered into merger deal with Amgen under which Amgen will acquire the Company for $52.00 per share in cash, representing an enterprise value of approximately $3.7 billion. The transaction is subject to the company's stockholder approval, regulatory approvals and other customary closing conditions, and is expected to close in the fourth quarter of 2022. Also Read: Amgen posts 2Q beat, trims earnings guidance; new drugs outperformRecent updates
Shareholder Returns
| CCXI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.1% | 4.0% | -2.3% |
| 1Y | 50.4% | 34.1% | 21.2% |
Return vs Industry: CCXI exceeded the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: CCXI exceeded the US Market which returned -19.8% over the past year.
Price Volatility
| CCXI volatility | |
|---|---|
| CCXI Average Weekly Movement | 31.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CCXI's share price has been volatile over the past 3 months.
Volatility Over Time: CCXI's weekly volatility has increased from 18% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 178 | n/a | www.chemocentryx.com |
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis.
ChemoCentryx, Inc. Fundamentals Summary
| CCXI fundamental statistics | |
|---|---|
| Market cap | US$3.74b |
| Earnings (TTM) | -US$133.09m |
| Revenue (TTM) | US$37.28m |
Is CCXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CCXI income statement (TTM) | |
|---|---|
| Revenue | US$37.28m |
| Cost of Revenue | US$71.86m |
| Gross Profit | -US$34.58m |
| Other Expenses | US$98.51m |
| Earnings | -US$133.09m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.85 |
| Gross Margin | -92.76% |
| Net Profit Margin | -357.01% |
| Debt/Equity Ratio | 10.5% |
How did CCXI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/10/23 05:05 |
| End of Day Share Price | 2022/10/19 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ChemoCentryx, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | B. Riley Securities, Inc. |
| Harshita Polishetty | B. Riley Securities, Inc. |
| Dae Gon Ha | BTIG |